Viibryd generic
Viibryd is an antidepressant drug owned by Allergan. The active ingredient in Viibryd is vilazodone hydrochloride. It was first authorised for market use on 21 January, 2011. The drug is available in tablet form for oral administration.
When will Viibryd generic be available?
The generic versions of Viibryd are yet to be released. The predictions are that these would be available after 31 July, 2023. The last patent of Viibryd is set to expire on 5 June, 2022, however, due to extensions via the patent term restoration, the generics may not be available until later.
Viibryd uses
Viibryd is used for the treatment of Major Depressive Disorder (MDD). Its active ingredient, vilazodone hydrochloride, works by helping to restore the balance of certain natural substances (serotonin) in the brain which aids in improving mood, sleep, appetite and energy level of patients.
Viibryd patent expiration
Viibryd has a total of 8 patents, and the patents which are impacting the release of Viibryd Generic are US8236804, and US8193195. These patents are expected to expire on 5 June, 2022. Below is the details of the patent: